Key result
COVID-19 acute myocardial injury linked to ~51% mortality and accelerated non-calcified plaque progression.
Why the study?
The global burden of post-acute sequelae of COVID-19 presents an ongoing challenge to cardiovascular medicine, requiring synthesis of acute and long-term cardiovascular impacts, molecular mechanisms, and management strategies.
Does COVID-19 infection increase the risk of major adverse cardiovascular events and accelerate vascular aging?
Does COVID-19 infection increase the risk of major adverse cardiovascular events and accelerate vascular aging?
COVID-19 acts as an independent, long-term risk factor for cardiovascular disease, accelerating vascular aging and increasing MACE risk, which necessitates structured long-term follow-up and vaccination.
PASC cardiovascular burden warrants ongoing clinical vigilance; leaves open targeted therapies and mechanisms for prospective trials.
By 2025, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been redefined from a primary respiratory pathogen to a multisystemic threat with profound cardiovascular implications. While acute mortality has stabilized, the global burden of post-acute sequelae of COVID-19 (PASC) presents a significant challenge to cardiovascular medicine, affecting individuals regardless of initial infection severity.This review synthesizes the latest scientific data (2024–2026) regarding the acute and long-term cardiovascular impacts of COVID-19, examining molecular mechanisms, accelerated vascular aging, and clinical management strategies. A comprehensive review of longitudinal cohort studies (e.g., UK Biobank, CARTESIAN study), meta-analyses involving over 10 million participants, and recent consensus statements from the ESC and ACC was conducted. Data were analyzed focusing on hazard ratios (HR) for major adverse cardiovascular events (MACE) and physiological markers of arterial stiffness.Acute COVID-19 infection is associated with myocardial injury in ~25% of hospitalized patients, significantly increasing mortality risk (51.2% vs 4.5%). Pathophysiologically, the virus utilizes ACE2 receptors for entry, leading to RAAS dysregulation, cytokine storms, and "immunothrombosis." Long-term data reveal a paradigm of accelerated vascular aging; survivors exhibit increased pulse wave velocity (PWV), with women experiencing biological aging of the vasculature by up to 5–10 years. Furthermore, COVID-19 accelerates non-calcified atherosclerotic plaque progression, tripling the risk of plaque rupture up to three years post-infection. Autonomic dysfunction is highly prevalent, with up to 31% of symptomatic Long COVID patients meeting the criteria for Postural Orthostatic Tachycardia Syndrome (POTS). Genetic factors, specifically non-O blood types, correlate with a 65% higher risk of MACE following severe infection.COVID-19 acts as an independent, long-term risk factor for cardiovascular disease. The cardiovascular "imprint" of the virus necessitates structured long-term follow-up, including cardiopulmonary exercise testing and aggressive management of traditional risk factors. Vaccination remains the primary protective strategy, significantly reducing the HR for heart failure and stroke compared to unvaccinated cohorts.
No takes yet. Share an insight, caveat, or question.
N et al. (2026) conducted a review in COVID-19-Induced Cardiovascular Pathology (n=10,000,000). COVID-19 infection vs. Uninfected individuals was evaluated. COVID-19 acts as an independent cardiovascular risk factor, with acute myocardial injury increasing mortality (51.2% vs 4.5%) and accelerating non-calcified atherosclerotic plaque progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: